QuantiFERON Access Clinical Performance Study Protocol
Withdrawn
- Conditions
- Tuberculosis (TB)
- Registration Number
- NCT04243031
- Lead Sponsor
- QIAGEN Gaithersburg, Inc
- Brief Summary
Approximately 225 samples, obtained from participants with varying risk factors for TB infection and disease, will be tested using the QFT Access Kit and the comparator device QFT-Plus.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
-
- Be ≥ 18 years of age,
-
- Have received no TB treatment or received treatment for less than 14 consecutive days.
-
- Provide Informed Consent.
Exclusion Criteria
-
- They do not meet the inclusion criteria,
-
- Blood handling was not completed using QFT-Plus
-
- Incubation was <16 and >24 hours
-
- Improperly collected and/or stored samples per Instructions For Use
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TB Result At time of enrollment QFT Access result compared to the QFT-Plus result (positive, negative)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie QFT Access's detection of TB infection compared to QFT-Plus?
How does QFT Access's clinical accuracy compare to standard TB diagnostic tools like T-SPOT.TB?
Which biomarkers are most predictive of TB infection status in the NCT04243031 study cohort?
What are the potential cross-reactivity issues with QFT Access in latent vs active TB cases?
How does the QuantiFERON Access assay performance compare to other interferon-gamma release assays in high-risk populations?